SCHEMBL19086324

SCHEMBL19086324

Cc1c(Br)cccc1OCc1ccccc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.76
L3MBTL1 Q9Y468 3/20 0.76
MAPT P10636 3/20 0.76
MAPK1 P28482 1/20 0.76
HTR6 P50406 1/20 0.51
LIPE Q05469 1/20 0.50
PTGER1 P34995 1/20 0.49
EDNRA P25101 1/20 0.48
MAPK14 Q16539 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
HTR1A P08908 2/20 0.47
DRD2 P14416 1/20 0.47
ADRA1D P25100 1/20 0.47
ADRA1A P35348 1/20 0.47
ADRA1B P35368 1/20 0.47
MAOB P27338 1/20 0.46
LTA4H P09960 1/20 0.45
MRGPRX4 Q96LA9 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19612191 0.87 MAPT (1.00) TDP1L3MBTL1MAPTMAPK1HTR6
SCHEMBL9340084 0.86 MAPT (0.65) TDP1L3MBTL1MAPTMAPK1HTR6
SCHEMBL31725934 0.86 MAPT (0.65) TDP1L3MBTL1MAPTMAPK1HTR6
SCHEMBL1028222 0.83 MAPT (0.53) TDP1L3MBTL1MAPTMAPK1HTR1A
SCHEMBL29414783 0.83 MAPT (0.59) TDP1L3MBTL1MAPTMAPK1LIPE
SCHEMBL1081189 0.83 MAPT (0.59) TDP1L3MBTL1MAPTMAPK1LIPE
SCHEMBL2880443 0.81 MAPT (0.81) TDP1L3MBTL1MAPTMAPK1HTR6
SCHEMBL18171750 0.81 TDP1 (0.58) TDP1L3MBTL1MAPTMAPK1LIPE
SCHEMBL20539690 0.81 MAOB (0.50) TDP1L3MBTL1MAPTMAPK1SMN1; SMN2
SCHEMBL1513408 0.81 MAPT (0.57) TDP1L3MBTL1MAPTMAPK1LIPE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190016681-A1 INHIBITORS OF THE PD-1/PD-L1 PROTEIN/PROTEIN INTERACTION RIJKSUNIVERSITEIT GRONINGEN (NL) 2019-01-17 US disclosed
US-20190016681-A1 INHIBITORS OF THE PD-1/PD-L1 PROTEIN/PROTEIN INTERACTION RIJKSUNIVERSITEIT GRONINGEN (NL) 2019-01-17 US disclosed
EP-3400213-A1 INHIBITORS OF THE PD-1/PD-L1 PROTEIN/PROTEIN INTERACTION Rijksuniversiteit Groningen (NL) 2018-11-14 EP disclosed
WO-2017118762-A1 INHIBITORS OF THE PD-1/PD-L1 PROTEIN/PROTEIN INTERACTION RIJKSUNIVERSITEIT GRONINGEN (NL) 2017-07-13 WO disclosed
WO-2017118762-A1 INHIBITORS OF THE PD-1/PD-L1 PROTEIN/PROTEIN INTERACTION RIJKSUNIVERSITEIT GRONINGEN (NL) 2017-07-13 WO disclosed
EP-3190103-A1 INHIBITORS OF THE PD-1/PD-L1 PROTEIN/PROTEIN INTERACTION Rijksuniversiteit Groningen (NL) 2017-07-12 EP disclosed
EP-3190103-A1 INHIBITORS OF THE PD-1/PD-L1 PROTEIN/PROTEIN INTERACTION Rijksuniversiteit Groningen (NL) 2017-07-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190016681-A1 INHIBITORS OF THE PD-1/PD-L1 PROTEIN/PROTEIN INTERACTION PDCD1, CD274, PDCD1LG2 TDP1 1926/4885L3MBTL1 1347/4885MAPT 3038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.